Search results for "Clinical Study"

showing 10 items of 211 documents

Anthropometric measures of 9-to 10-year-old native tibetan children living at 3700 and 4300m above sea level and han Chinese living at 3700m

2015

A high residential altitude impacts on the growth of children, and it has been suggested that linear growth (height) is more affected than body mass. The aim of the present study was to estimate the prevalence of obesity, overweight, underweight, and stunting in groups of native Tibetan children living at different residential altitudes (3700 vs 4300 m above sea level) and across ancestry (native Tibetan vs Han Chinese children living at the same altitude of 3700 m), as well as to examine the total effect of residential altitude and ancestry with stunting. Two cross-sectional studies of 1207 school children aged 9 to 10 years were conducted in Lhasa in 2005 and Tingri in 2007. Conventional …

*altitude *anthropometry article body height body mass chest circumference child controlled study cross- sectional study diet dietary intake disease association disease severity female Han Chinese human major clinical study male *obesity/ep [Epidemiology] *obesity/et [Etiology] prevalence priority journal school child sex ratio social status *stunting/ep [Epidemiology] *stunting/et [Etiology] Tibetan (people) *underweight/ep [Epidemiology] *underweight/et [Etiology] waist circumference
researchProduct

Quantifying and addressing the prevalence and bias of study designs in the environmental and social sciences

2020

Building trust in science and evidence-based decision-making depends heavily on the credibility of studies and their findings. Researchers employ many different study designs that vary in their risk of bias to evaluate the true effect of interventions or impacts. Here, we empirically quantify, on a large scale, the prevalence of different study designs and the magnitude of bias in their estimates. Randomised designs and controlled observational designs with pre-intervention sampling were used by just 23% of intervention studies in biodiversity conservation, and 36% of intervention studies in social science. We demonstrate, through pairwise within-study comparisons across 49 environmental da…

0106 biological sciencesResearch designScientific communitySCIENTIFIC COMMUNITYMedio ambiente naturalsosiaalitieteetPsychological interventionGeneral Physics and AstronomySocial SciencesQH7501 natural sciencesEnvironmental impact//purl.org/becyt/ford/1 [https]010104 statistics & probability/706/648CredibilityPrevalenceSocial scienceComputingMilieux_MISCELLANEOUSGEMultidisciplinaryEcologyQarticleSampling (statistics)Biodiversitynäyttöön perustuvat käytännötsatunnaistetut vertailukokeetENVIRONMENTAL IMPACTResearch designResearch DesignScale (social sciences)[SDE]Environmental SciencesH1ScienceEnvironment010603 evolutionary biologyGeneral Biochemistry Genetics and Molecular BiologySocial sciencesBiastutkimusmenetelmätQH541/704/172/4081Humans0101 mathematics//purl.org/becyt/ford/1.6 [https]ympäristötieteetpoliittinen päätöksentekoClinical study designmetodologia/706/689General Chemistry15. Life on landEcologíaLiteraturePairwise comparisonObservational study/631/158luotettavuusBias; Biodiversity; Ecology; Environment; Humans; Literature; Prevalence; Research Design; Social SciencesNature Communications
researchProduct

Improving scientific rigour in conservation evaluations and a plea deal for transparency on potential biases

2020

Abstract The delivery of rigorous and unbiased evidence on the effects of interventions lay at the heart of the scientific method. Here we examine scientific papers evaluating agri‐environment schemes, the principal instrument to mitigate farmland biodiversity declines worldwide. Despite previous warnings about rudimentary study designs in this field, we found that the majority of studies published between 2008 and 2017 still lack robust study designs to strictly evaluate intervention effects. Potential sources of bias that arise from the correlative nature are rarely mentioned, and results are still promoted by using a causal language. This lack of robust study designs likely results from …

0106 biological sciencesagri‐environment schemelcsh:QH1-199.5Psychological interventionIntervention effectlcsh:General. Including nature conservation geographical distribution010603 evolutionary biology01 natural sciencesRigourPleaorganic farmingbefore after control impactVDP::Matematikk og Naturvitenskap: 400::Basale biofag: 470Ecology Evolution Behavior and SystematicsNature and Landscape ConservationEcology010604 marine biology & hydrobiologyClinical study designevaluation of conservation interventionsPrincipal (computer security)biodiversity | causal languageRisk analysis (engineering)meta‐analysisMeta-analysisTransparency (graphic)PsychologyConservation Letters
researchProduct

A Hazelnut-Enriched Diet Modulates Oxidative Stress and Inflammation Gene Expression without Weight Gain

2019

Introduction. Inflammation is associated with obesity condition and plays a pivotal role in the onset and progression of many chronic diseases. Among several nutraceutical foods, hazelnuts (Corylus avellana L.) are considered an excellent anti-inflammatory and hypolipidemic food being the second richest source of monounsaturated fatty acids among nuts and because they are rich in vitamins, minerals, and phenolic compounds. Materials and Methods. A prospective pilot clinical trial on 24 healthy volunteers who consumed daily, as a snack, 40 g of hazelnuts (261.99 kcal/1096.17 kJ) for six weeks was conducted. Anthropometric measurements, body composition analysis, and nutrigenomic analysis on …

0301 basic medicineAgingAntioxidantArticle Subjectmedicine.medical_treatmentGene ExpressionInflammationPilot Projects030204 cardiovascular system & hematologyBiologymedicine.disease_causeSettore BIO/09BiochemistryCalcitriol receptorCorylus; Gene Expression; Healthy Volunteers; Humans; Inflammation; Middle Aged; Obesity; Oxidative Stress; Pilot Projects; Prospective Studies03 medical and health sciences0302 clinical medicineNutraceuticalCorylusmedicineHumansFood scienceObesityProspective Studieslcsh:QH573-671Inflammationlcsh:CytologySettore BIO/12Cell BiologyGeneral MedicineMiddle Agedmedicine.diseaseObesityHealthy VolunteersOxidative Stress030104 developmental biologyMethylenetetrahydrofolate reductasebiology.proteinClinical Studymedicine.symptomWeight gainOxidative stress
researchProduct

The prevalence of malnutrition according to the new ESPEN definition in four diverse populations

2016

© 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.Background & aims: Consensus on the definition of malnutrition has not yet been reached. Recently, The European Society for Clinical Nutrition and Metabolism (ESPEN) proposed a consensus definition of malnutrition. The aim of the present study was to describe the prevalence of malnutrition according to the ESPEN definition in four diverse populations. Methods: In total, 349 acutely ill middle-aged patients, 135 geriatric outpatients, 306 healthy old individuals and 179 healthy young individuals were included in the study. Subjects were screened for risk of malnutrition using the SNAQ. The ESPEN definition of maln…

0301 basic medicineGerontologyMalePediatricsNutritional SciencesCritical Care and Intensive Care MedicineThinness/etiologygeriatric patientBody Mass IndexNutritional Sciences/methods0302 clinical medicineunderweightWeight loss/dk/atira/pure/sustainabledevelopmentgoals/zero_hungerPrevalenceMedicine030212 general & internal medicineYoung adultcomparative studypathophysiologyhealth care organizationNutrition and Dieteticsta3141Scientificta3142Middle AgedEuropenutritional assessmentElder Nutritional Physiological PhenomenaoutpatientAcute DiseasePractice Guidelines as TopicBody CompositionFemalemedicine.symptomRisk assessmentSocieties ScientificPredictive validityAdultRiskmedicine.medical_specialtyConsensusgeriatric nutritionNutritional Statusmalnutritionadult; aged; Article; body mass; controlled study; disease predisposition; fat free mass; female; geriatric patient; human; major clinical study; male; malnutrition; middle aged; nutritional assessment; outpatient; population research; predictive validity; prevalence; risk assessment; short nutritional assessment questionnaire; weight reduction; acute disease; body composition; comparative study; consensus; Europe; geriatric assessment; geriatric nutrition; health care organization; malnutrition; nutritional assessment; nutritional science; nutritional status; pathophysiology; practice guideline; procedures; risk; risk assessment; underweight; young adult Acute Disease; Adult; Aged; Body Composition; Body Mass Index; Consensus; Elder Nutritional Physiological Phenomena; Europe; Female; Geriatric Assessment; Humans; Male; Malnutrition; Middle Aged; Nutrition Assessment; Nutritional Sciences; Nutritional Status; Practice Guidelines as Topic; Prevalence; Risk; Risk Assessment; Societies Scientific; Thinness; Young Adult; Body mass index; Definition; Fat free mass index; Malnutrition; PrevalenceRisk AssessmentArticleEurope/epidemiology03 medical and health sciencesYoung AdultThinnessFat free mass indexHumanscontrolled studyhumanproceduresSDG 2 - Zero HungerGeriatric AssessmentAged030109 nutrition & dieteticsbusiness.industrypractice guidelinedisease predispositionDefinitionNUTRITION&DIETETICSmedicine.diseasemajor clinical studybody masspredictive validityMalnutritionNutrition Assessmentfat free massweight reductionshort nutritional assessment questionnairenutritional scienceNutritional sciencebusinessSocietiespopulation researchBody mass indexMalnutrition/diagnosisClinical Nutrition
researchProduct

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

2016

Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).Methods:Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85 mg m -2, folinic acid 400 mg m -2, and 5-fluorouracil (400 mg m -2 bolus then 2400 mg m -2 over 46 h). Radiographic evaluation was performed every 8 weeks until progression. Primary endpoint was objective response rate.Results:Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8-77.6); complete response was observed in …

0301 basic medicineMaleCancer ResearchOrganoplatinum CompoundsLeucovorinPhases of clinical researchmedicine.disease_causeGastroenterology0302 clinical medicineadvanced colorectal cancerAntineoplastic Combined Chemotherapy ProtocolsClinical endpointNeoplasm MetastasisNecitumumabModified FOLFOX6Aged 80 and overnecitumumabAntibodies MonoclonalMiddle AgedOxaliplatinTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisFemaleKRASFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyEGFRNeutropeniamodified FOLFOX6Antibodies Monoclonal HumanizedDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciencesFolinic acidInternal medicinemedicineKRASHumansAdvanced colorectal cancerAgedbusiness.industrymedicine.diseaseSurvival AnalysisSurgeryOxaliplatinCancérologie030104 developmental biologyClinical StudybusinessNecitumumabBritish Journal of Cancer
researchProduct

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

2017

Supplemental Digital Content is available in the text.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT-LymphocytesEpitopes T-LymphocyteT-Cell Antigen Receptor SpecificityImmunotherapy AdoptiveEpitopeCohort StudiesExon0302 clinical medicineimmune system diseasesImmunology and AllergyMedicineProtein IsoformsChildAged 80 and overbiologyCD19CART-19B-ALLMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomaepitope-lossmedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisChild PreschoolComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleClone (B-cell biology)Gene isoformAdultAdolescentRecombinant Fusion ProteinsImmunologyAntigens CD19Receptors Antigen T-CellCancer VaccinesCD1903 medical and health sciencesYoung AdultAntigenHumansAgedPharmacologybusiness.industryInfant NewbornisoformsInfantImmunotherapy030104 developmental biologyImmunologybiology.proteinClinical StudyTumor EscapeBone marrowbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct